Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival

Transplantation

Volumn 62, Issue 3, 1996, Pages 336-342

  Candinas, Daniel ^a   Lesnikoski, Beth Ann ^a   Robson, Simon C ^a   Miyatake, Tsukasa ^a   Scesney, Susanne M ^b   Marsh Jr , Henry C ^b   Ryan, Una S ^b   Dalmasso, Agustin P ^c   Hancock, Wayne W ^a   Bach, Fritz H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b T Cell Sciences Inc   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C3B RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOMODULATION; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; XENOTRANSPLANTATION;

EID: 9444256949     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199608150-00006     Document Type: Article

References (30)

1. Auchincloss H. Xenogeneic transplantation. Transplantation 1988; 46: 1.
2. Bach FH, Robson SC, Winkler H, et al. Barriers to xenotransplantation. Nature Med 1995; 1: 869.
3. Dalmasso AP. The complement system in xenotransplantation. Immunopharmacology 1992; 24: 149.
4. Vogel CW, Smith CA, Muller EH. Cobra venom factor: structural homology with the third component of human complement. J Immunol 1984; 133: 3235.
5. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
6. Ward PA, Till GO, Hatherill JR, Annesley TM, Kunkel RG. Systemic complement activation, lung injury, and products of lipid peroxidation. J Clin Invest 1985; 76: 517.
7. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: potential for prevention of xenograft rejection. Transplantation 1991; 32: 530.
8. Ryan US. Complement inhibitory therapeutics and xenotransplantation. Nature Med 1995; 1: 967.
9. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146.
10. Weisman HF, Bartow T, Leppo MK, et al. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 1990; 103: 64.
11. Xia W, Fearon DT, Moore FJ, Schoen FJ, Ortiz F, Kirkman RL. Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Transplant Proc 1992; 24: 479.
12. Pruitt SK, Baldwin WM, Marsh HJ, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868.
13. Xia W, Fearon DT, Kirkman RL. Effect of repetitive doses of soluble human complement receptor type 1 on survival of discordant cardiac xenografts. Transplant Proc 1993; 25: 410.
14. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
15. Beukelman CJ, Aerts PC, van Dijk H, Willers JM. A one-step isolation procedure for phospholipase A2-free cobra venom factor by fast protein liquid chromatography. J Immunol Methods 1987; 97: 119.
16. Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 10: 1059.
17. Hancock WW, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules and the pathogenesis of chronic rejection of rat renal allografts. Transplant 1993; 56: 643.
18. Hancock WW, Sayegh MH, Sablinski T, Kut JP, Jw K-W, Milford EL. Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy. Transplantation 1992; 53: 1276.
19. Mayer MM. Complement and complement fixation. In: Kabat K, Mayer MM, eds. Experimental immunochemistry. Springfield, IL: Thomas, 1961: 113.
20. Platts-Mills TAE, Ishizaka K. Activation of the alternate pathway of human complement by rabbit cells. J Immunol 1974; 113: 348.
21. Candinas D, Bach FH, Hancock WW. Delayed xenograft rejection in complement depleted T cell-deficient rat recipients of guinea pig cardiac grafts. Transplant Proc 1996; 28: 678.
22. Bach FH, Robson SC, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol Rev 1994; 141: 5.
23. Miyagawa S, Hirose H, Shirakura R, Matsumoto M, Uenaka A, Kitamura H. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
24. Bach FH, Turman MA, Vercellotti GM, Platt JL, Dalmasso AP. Accommodation: a working paradigm for progressing toward discordant xenografting. Transplant Proc 1991; 23: 205.
25. Cozzi E, White D. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1: 964.
26. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today 1993; 14: 500.
27. Schirmer WJ, Schirmer JM, Naff GB, Fry DE. Complement depletion alters the systemic and visceral hemodynamic response to endotoxemia. Curr Surg 1988; 45: 288.
28. Baldwin IW, Pruitt SK, Brauer RB, Daha RM, Sanfilippo F. Complement in organ transplantation. Transplantation 1995; 59: 797.
29. Hutton RA, Warrell DA. Action of snake venom components on the haemostatic system. Blood Rev 1991; 7: 176.
30. Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991; 12: 338.